vs
Side-by-side financial comparison of DuPont (DD) and Organon & Co. (OGN). Click either name above to swap in a different company.
DuPont is the larger business by last-quarter revenue ($1.7B vs $1.5B, roughly 1.2× Organon & Co.). Organon & Co. runs the higher net margin — 10.0% vs 9.8%, a 0.2% gap on every dollar of revenue. On growth, DuPont posted the faster year-over-year revenue change (4.0% vs -3.5%). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-4.7% CAGR vs -27.2%).
DuPont de Nemours, Inc., commonly shortened to DuPont, is an American multinational chemical company first formed in 1802 by French-American chemist and industrialist Éleuthère Irénée du Pont de Nemours. The company played a major role in the development of the U.S. state of Delaware and first arose as a major supplier of gunpowder.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
DD vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $1.5B |
| Net Profit | $164.0M | $146.0M |
| Gross Margin | 35.8% | 53.6% |
| Operating Margin | — | — |
| Net Margin | 9.8% | 10.0% |
| Revenue YoY | 4.0% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $0.36 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.7B | $1.5B | ||
| Q4 25 | $-2.5B | $1.5B | ||
| Q3 25 | $3.1B | $1.6B | ||
| Q2 25 | $3.3B | $1.6B | ||
| Q1 25 | $3.1B | $1.5B | ||
| Q4 24 | $3.1B | $1.6B | ||
| Q3 24 | $3.2B | $1.6B | ||
| Q2 24 | $3.2B | $1.6B |
| Q1 26 | $164.0M | $146.0M | ||
| Q4 25 | $-126.0M | $-205.0M | ||
| Q3 25 | $-123.0M | $160.0M | ||
| Q2 25 | $59.0M | $145.0M | ||
| Q1 25 | $-589.0M | $87.0M | ||
| Q4 24 | $-118.0M | $109.0M | ||
| Q3 24 | $454.0M | $359.0M | ||
| Q2 24 | $178.0M | $195.0M |
| Q1 26 | 35.8% | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | 38.9% | 53.5% | ||
| Q2 25 | 37.3% | 54.8% | ||
| Q1 25 | 37.4% | 55.6% | ||
| Q4 24 | 36.4% | 56.3% | ||
| Q3 24 | 37.4% | 58.3% | ||
| Q2 24 | 37.1% | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | -9.8% | ||
| Q3 25 | 10.6% | 15.2% | ||
| Q2 25 | 9.4% | 14.4% | ||
| Q1 25 | -14.0% | 6.7% | ||
| Q4 24 | 1.4% | 8.1% | ||
| Q3 24 | 18.4% | 13.1% | ||
| Q2 24 | 9.3% | 14.6% |
| Q1 26 | 9.8% | 10.0% | ||
| Q4 25 | 4.9% | -13.6% | ||
| Q3 25 | -4.0% | 10.0% | ||
| Q2 25 | 1.8% | 9.1% | ||
| Q1 25 | -19.2% | 5.8% | ||
| Q4 24 | -3.8% | 6.8% | ||
| Q3 24 | 14.2% | 22.7% | ||
| Q2 24 | 5.6% | 12.1% |
| Q1 26 | $0.36 | $0.55 | ||
| Q4 25 | $-0.30 | $-0.78 | ||
| Q3 25 | $-0.29 | $0.61 | ||
| Q2 25 | $0.14 | $0.56 | ||
| Q1 25 | $-1.41 | $0.33 | ||
| Q4 24 | $-0.28 | $0.42 | ||
| Q3 24 | $1.08 | $1.38 | ||
| Q2 24 | $0.42 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $710.0M | — |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $14.2B | — |
| Total Assets | $21.4B | — |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $710.0M | — | ||
| Q4 25 | $715.0M | $574.0M | ||
| Q3 25 | $2.0B | $672.0M | ||
| Q2 25 | $1.8B | $599.0M | ||
| Q1 25 | $1.8B | $547.0M | ||
| Q4 24 | $1.9B | $675.0M | ||
| Q3 24 | $1.6B | $763.0M | ||
| Q2 24 | $1.5B | $704.0M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | $8.6B | ||
| Q3 25 | $7.0B | $8.8B | ||
| Q2 25 | $5.3B | $8.9B | ||
| Q1 25 | $5.3B | $9.0B | ||
| Q4 24 | $5.3B | $8.9B | ||
| Q3 24 | $7.2B | $8.7B | ||
| Q2 24 | $7.2B | $8.7B |
| Q1 26 | $14.2B | — | ||
| Q4 25 | $13.9B | $752.0M | ||
| Q3 25 | $22.9B | $906.0M | ||
| Q2 25 | $23.1B | $733.0M | ||
| Q1 25 | $22.8B | $542.0M | ||
| Q4 24 | $23.4B | $472.0M | ||
| Q3 24 | $24.2B | $493.0M | ||
| Q2 24 | $23.3B | $144.0M |
| Q1 26 | $21.4B | — | ||
| Q4 25 | $21.6B | $12.9B | ||
| Q3 25 | $38.0B | $13.6B | ||
| Q2 25 | $36.6B | $13.5B | ||
| Q1 25 | $36.0B | $13.2B | ||
| Q4 24 | $36.6B | $13.1B | ||
| Q3 24 | $37.5B | $12.8B | ||
| Q2 24 | $36.6B | $12.2B |
| Q1 26 | 0.22× | — | ||
| Q4 25 | 0.23× | 11.49× | ||
| Q3 25 | 0.31× | 9.74× | ||
| Q2 25 | 0.23× | 12.14× | ||
| Q1 25 | 0.23× | 16.52× | ||
| Q4 24 | 0.23× | 18.81× | ||
| Q3 24 | 0.30× | 17.75× | ||
| Q2 24 | 0.31× | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DD
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
